Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies

D Fredman, R McNeil, O Eldar, A Leader… - Journal of Thrombosis …, 2024 - Springer
Background Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban
are preferred over vitamin K antagonists for the treatment of venous thromboembolism …

Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta …

H Ning, N Yang, Y Ding, H Chen, L Wang, Y Han… - Medicina Clínica, 2023 - Elsevier
Abstract Introduction Direct oral anticoagulants (DOACs) could effectively prevent the
occurrence of cancer-associated venous thromboembolism (CAVTE), which incidence rate …

[PDF][PDF] Meta-Analysis of Risk Factors for Venous Thromboembolism in Patients with Gynecologic Malignant Tumors

J Pan, G Zhao - Alternative Therapies in Health and …, 2024 - alternative-therapies.com
Objective• This study aims to investigate the risk factors associated with the development of
venous thromboembolism (VTE) in patients diagnosed with gynecologic malignant tumors …

Pulmonary embolism in patients with cancer: an updated and operative guide for diagnosis and management

IC Network, G Network, L Liberale - internationaljournalofcardiology.com
Pulmonary embolism in patients with cancer: an updated and operative guide for diagnosis
and management Amedeo Tirandi 1 , MD; Alberto Preda 2 , MD; Federico Carbone 1,3 , MD …

[引用][C] Advancing management of pulmonary thromboembolic disease: from acute pulmonary embolism to pulmonary hypertension

C Samaranayake - 2023 - espace.library.uq.edu.au
Background and Aims Pulmonary thromboembolic disease encompasses a wide range of
clinical presentations during several stages of disease evolution from acute pulmonary …